Lanean...
Improving Conventional or Low Dose Metronomic Chemotherapy with Targeted Antiangiogenic Drugs
One of the most significant developments in medical oncology practice has been the approval of various antiangiogenic drugs for the treatment of a number of different malignancies. These drugs include bevacizumab (Avastin®), the anti-VEGF monoclonal antibody. Thus far, bevacizumab appears to induce...
Gorde:
| Egile nagusia: | |
|---|---|
| Formatua: | Artigo |
| Hizkuntza: | Inglês |
| Argitaratua: |
Korean Cancer Association
2007
|
| Gaiak: | |
| Sarrera elektronikoa: | https://ncbi.nlm.nih.gov/pmc/articles/PMC2739367/ https://ncbi.nlm.nih.gov/pubmed/19746237 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.4143/crt.2007.39.4.150 |
| Etiketak: |
Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!
|